KRAS and neoplasm: The concordance of KRAS mutation in CTCs with paired primary tissues of CRCs was compared in all nine studies, but only four studies were evaluated for BRAF mutation of CTCs, three studies were analyzed for KRAS mutation of CTCs with tumor status, and one study assessed mutations among primary tumors, CTCs, and metastatic lesions [30–38].